Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in oncology.
Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
Zacks Investment Research on MSN
INCY wins EC approval for label expansion of oncology drug Zynyz
Incyte INCY recently announced that the European Commission has approved a label expansion of oncology drug Zynyz ...
A drug which can slow the growth of brain tumours has been approved for use on NHS Scotland, following a campaign by those affected ...
Trump told pregnant women not to take Tylenol as he promoted unproven ties to autism, and touted a generic drug to treat the ...
13hOpinion
Virginia’s Prescription Drug Affordability Board needs guardrails to protect patient access
As a full-time practicing medical oncologist in Winchester, I spend my days with Virginians who bravely fight cancer. Sadly, ...
A drug which can slow the growth of brain tumours has been approved for use on NHS Scotland, following a campaign by those affected ...
In response to statements made by the White House, The American College of Obstetrics and Gynecologists (ACOG) strongly ...
A guide to Medicare coverage for breast cancer diagnosis and treatment, including cost differences between Original Medicare ...
But the FDA’s decision does not preclude CMS from determining that the higher dose is not reasonable and necessary — ...
Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results